1. EP1120 Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: outcomes from an Institutional series. (1st November 2019) Authors: Falcone, F; Normanno, N; Losito, N; Scognamiglio, G; Esposito Abate, R; Chicchinelli, N; Scaffa, C; Greggi, S Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A584 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. (7th August 2017) Authors: Normanno, N; Esposito Abate, R; Lambiase, M; Forgione, L; Cardone, C; Iannaccone, A; Sacco, A; Rachiglio, A M; Martinelli, E; Rizzi, D; Pisconti, S; Biglietto, M; Bordonaro, R; Troiani, T; Latiano, T P; Giuliani, F; Leo, S; Rinaldi, A; Maiello, E; Ciardiello, F Journal: Annals of oncology Issue: Volume 29:Number 1(2018) Page Start: 112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗